Resistance to antimicrobial agents in patients with non-cystic fibrosis (CF) bronchiectasis Source: Eur Respir J 2005; 26: Suppl. 49, 640s Year: 2005
Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Azithromycin in chronic respiratory infections with pseudomonas aeruginosa in patients without cystic fibrosis Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host Year: 2008
Emerging pathogens in cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=66 Year: 2006
Daily versus weekly azithromycin in cystic fibrosis patients Source: Eur Respir J 2007; 30: 487-495 Year: 2007
Fosfomycin for pseudomonas related exacerbations of cystic fibrosis Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools Year: 2008
Eradication regime of methicillin resistant staphylococcus aureus lung infection in cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013
Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016
Function of ciliary epithelium in the patients with cystic fibrosis (CF) with chronic Ps.aeruginosa infection and without Ps.aeruginosa Source: Eur Respir J 2001; 18: Suppl. 33, 125s Year: 2001
Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis}, Source: Eur Respir J 2012; 40: 1014-1023 Year: 2012
Chronic use of azithromycin in CF is associated with a substantial increase in macrolide resistance of S. aureus and haemophilus Source: Annual Congress 2006 - Cystic fibrosis lung disease: molecules images and drugs Year: 2006
The characteristics of the minimum inhibitory concentration of antibiotics on pulmonary infections in patients with cystic fibrosis Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015
Early eradication of pseudomonas aeruginosa (PA) in cystic fibrosis patients (CF): Which is the best treatment? Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013
Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections Source: Eur Respir J 2012; 40: 227-238 Year: 2012
A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013
LATE-BREAKING ABSTRACT: Is there a relationship between use of inhaled antibiotics and prevalence of fungal isolates in the respiratory secretions of people with cystic fibrosis? A retrospective data analysis Source: International Congress 2015 – Cystic fibrosis: assessment and treatment Year: 2015
Managing antimicrobial resistance in cystic fibrosis Source: International Congress 2014 – ERS/Lancet and Lancet Respiratory Medicine joint session: complicating infections in respiratory disease and critical care Year: 2014
Influence of the lung microbiome on antibiotic susceptibility of cystic fibrosis pathogens Source: Eur Respir Rev, 28 (152) 190041; 10.1183/16000617.0041-2019 Year: 2019
Patients with no cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa : Role of inhaled colistin Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014
Role of stenotrophomonas maltophilia infection in CF pulmonary exacerbations Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013